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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the efficacy of interventions for treating persistent pain in survivors of torture.
B A C K G R O U N D
Reports of torture and other ill-treatment come from over 150
countries (AI 2010). The International Rehabilitation Council for
Torture Victims (IRCT 2010) estimates that around 400,000 tor-
ture survivors live in the European Union alone, with similar es-
timates in the United States of America (USA) (Jaranson 1995).
Many diverse injuries are inflicted during torture and ill-treatment,
usually in conditions of poor nutrition and hygiene, to a highly
stressed individual, and without health care. The violence, extent,
and complexity of injuries often lie outside medical problems ad-
dressed in textbooks and in the scientific literature (Amris 2007),
and persistent pain is a common finding in survivors (Amris 2007;
Rasmussen 1990). Pain is defined by The International Associa-
tion for the Study of Pain as “an unpleasant sensory and emotional
experience associated with actual or potential tissue damage, or
described in terms of such damage” (IASP 1994). Persistent or
chronic pain is commonly defined as pain that is present for more
than three months, assuming the initial injury to have healed in
that time. In the case of injury from torture, which commonly
goes untreated, this may not be the case.
Unlike many other client groups, the health concerns of torture
survivors are defined not primarily by diagnosis or recognised clas-
sification systems but by their experience of torture and other ill-
treatment. Torture is a deliberate assault upon the body, the psy-
che, the identity and the integrity of the person, aiming to dehu-
manise, degrade, destroy or debilitate and render the individual
helpless. It is defined by the United Nations Convention against
Torture and Other Cruel, Inhuman or Degrading Treatment or
Punishment (CAT), Article 1 (UN 1984) as “any act by which se-
vere pain or suffering, whether physical or mental, is intentionally
inflicted on a person for such purposes as obtaining from him or
a third person information or a confession, punishing him for an
act he or a third person has committed or is suspected of having
committed, or intimidating or coercing him or a third person, or
for any reason based on discrimination of any kind, when such
pain or suffering is inflicted by or at the instigation of or with
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the consent or acquiescence of a public official or other person
acting in an official capacity. It does not include pain or suffering
arising only from, inherent in or incidental to lawful sanctions”
(UN 1984). By extension, torture undermines communities and
groups whose members are targeted, spreading distrust and fear
(Patel 2007). We will use the wider definition from the World
Medical Association (WMA 2006): “the deliberate, systematic or
wanton infliction of physical or mental suffering by one or more
persons acting alone or on the orders of any authority, to force
another person to yield information, to make a confession, or for
any other reason.”
Physical health problems related to torture have been widely docu-
mented (Jacob 2001; Moreno 2002; Norredam 2005; for reviews
see Jaranson 2011; Montgomery 2011; Quiroga 2005), as have
psychological health problems (e.g. Basoglu 2001; Johnson 2008;
Patel 2007). Torture-related physical health problems not only
cause disability and restricted functioning but also produce psy-
chological problems, compounding the impact on overall personal
and social functioning. Additionally, torture survivors in countries
of exile can experience many social, legal and practical difficulties
(e.g. seeking asylum, being subject to racist attacks, inadequate
housing, inability to communicate in the language of the host
country, and concerns for family and friends with whom they have
lost contact) which may take priority over their health problems;
they may also be uncertain about their rights to health care, which
may be restricted, and fearful of any perceived authority (Burnett
2001).
Torture survivors may not be recognised as such within the health
service (Crosby 2006; Eisenman 2003), and the health care offered
or accessible to them falls short of their needs (Amris 2007; Amris
2015; Berliner 2005; Burnett 2001; Quiroga 2005). Psychologi-
cal services offered by non-governmental organisations have very
variable methods and skills (Patel 2014); both they and main-
stream mental health services tend to have a poor understanding
of persistent pain, and may attribute it to evident psychological
disturbance, in particular post-traumatic stress.
Description of the condition
Physical torture is in most instances directed towards the muscu-
loskeletal system, aiming at producing soft tissue lesions and pain
and usually at leaving either no visible, or nonspecific, findings
after the acute stage. Random beatings, systematic beating of spe-
cific body parts (the head, palms, soles, and lumbar region), strap-
ping/binding, suspension by the extremities, forced positions for
extended periods, and electrical torture are frequent (Rasmussen
1990; Williams 2010). Other physical methods include asphyxi-
ation, near-drowning, stabbing, cutting, burning, and sexual as-
saults including hetero- and homosexual rape (Rasmussen 2006;
Olsen 2007).
Persistent pain in the musculoskeletal system is recognised as one
of the most frequent physical complaints presented by torture sur-
vivors (Amris 2007; Burnett 2001; Edston 2005; Olsen 2006;
Rasmussen 1990; Rasmussen 2006), but other pain has been de-
scribed and is often hard to classify or describe in terms of mecha-
nism (Amris 2007; Lund 2008; Rasmussen 1990;Williams 2010).
Survivors of torture are likely to present with complex and multi-
ple pains, and often with moderate to severe symptoms of depres-
sion, anxiety, and traumatic stress (Berliner 2005; Serraj 1996).
There is no basis for the widespread belief that pain from torture
is in some way produced by psychological disturbance, other than
pain triggered by re-experiencing traumatic events; the origin of
pain in torture does however add to the complexity of assessment
and treatment (Sjölund 2009).
Description of the intervention
Any treatment intended to relieve pain or improve function de-
spite ongoing pain is a possible intervention. Thus interventions
eligible for this review include pharmacotherapy by various routes
(oral, sublingual, topical), peripheral nerve blockade and other in-
jections, physiotherapy, psychological rehabilitative treatment, pe-
ripheral stimulation such as transcutaneous electrical nerve stimu-
lation (TENS), acupuncture, neuro-modulation (including spinal
cord stimulation), and complementary and alternative therapies.
How the intervention might work
There is no suggestion that interventions would work differently
in survivors of torture than in anyone who is not a survivor of
torture, only that (a) pain resulting from torture can be difficult
to understand in the light of current knowledge, and (b) that
survivors are, because of their experience, often hypersensitive to
medical procedures required for diagnosis and treatment.
Why it is important to do this review
In the era of evidence-based health care, there is considerable em-
phasis on services providing treatments demonstrated to be effec-
tive. However, health care of torture survivors is almost entirely
addressed within the psychological literature, with serious neglect
of physical sequelae and their treatment. Populations are diverse
in cultural, ethnic, religious and political backgrounds and are of-
ten unable to express themselves adequately in the language of the
host country. Compared to the many reviews of interventions for
psychological problems (see Jaranson 2011; Patel 2014), there are
few reviews of interventions for medical problems, and all of them
either brief and generalised (e.g. Quiroga 2005) or specific to par-
ticular injuries or treatments (e.g. Amris 2000a: Amris 2000b).
Most of the literature on physical health difficulties experienced by
torture survivors (before or without treatment) consists of clinical
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opinions and case studies (for review, see Mollica 2011; for exam-
ple, see Mckenna 2012). There are also descriptive studies which
enumerate the variety of health problems of survivors, often pub-
lished with the main aim of raising awareness and concern about
the issues (Jaranson 2011; Montgomery 2011; Quiroga 2005).
Of more concern here is that in developed countries, which have
contributed most to the literature on health care for refugee sur-
vivors of torture, the focus of clinical and research effort has been
on the psychological sequelae, often described in terms of post-
traumatic stress disorder (PTSD), rather than on the physical se-
quelae. This, combined with the slow spread of understanding
of pain mechanisms among some medical and paramedical spe-
cialties, including psychology and psychotherapy, means that re-
ported pain is often recorded as a psychosomatic presentation of
psychological disorder, reducing usefulness for the pain clinician
or researcher. This is reinforced by cultural influences, particularly
dualistic tendencies in medicine, and the political representation
of shared trauma as individual psychopathology (Bracken 1995;
Watters 2001).
O B J E C T I V E S
To assess the efficacy of interventions for treating persistent pain
in survivors of torture.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), cluster
RCTs, and quasi-RCTs (QRCTs). We wish to be as inclusive as
possible, and since we expect to find a small number of RCTs,
QRCTs are included; also because some methods of quasi-ran-
domisation used in underdeveloped country settings are unlikely
to introduce bias.
There will be no restrictions on publication type, status, language
or date, also to maximise search yield. We will include conference
abstracts and other reports if full details can be obtained from the
study authors, as relevant material is often published by torture
survivor centres themselves.
Types of participants
Participants must be identified as survivors of torture or ill-treat-
ment, consistent with the UN 1984 definition above, or at least
50% of the study population identified as such.
Torture survivors may be found among refugees, asylum seekers,
war survivors and survivors of organised violence, and in diverse
settings, such as prison, detention centre, refugee camp, accom-
modation centre, healthcare facility, and community. Participants
of all ages will be included.
Types of interventions
Interventions can be of any modality and provided by any practi-
tioner or self-administered, provided that they are primarily aimed
at pain relief. Comparators can be any alternative condition: no
intervention, waiting list, care as usual, standard care, alternative
treatment, or placebo condition.
Types of outcome measures
We will include a ’Summary of findings’ table as set out in the
PaPaS author guide (AUREF 2012) and recommended in the
Cochrane Handbook for Systematic Reviews of Interventions, chapter
4.6.6 (Higgins 2011), if sufficient data are available. The ’Sum-
mary of findings’ table will include outcomes of pain reduction,
quality of life indicators, global improvement/satisfaction and ad-
verse effects. These will be distinguished as immediate (end of
treatment), short-term (4 to 12 week), and longer-term (over 12
week) outcomes. We will use the GRADE approach (GRADEpro
GDT 2015) to assess the quality of evidence related to each of
the key outcomes (chapter 12, Higgins 2011), as appropriate. See
Appendix 1 for a further description of the GRADE system.
Primary outcomes
• Pain relief or reduction in pain as reported by the
participant, without which the study is not eligible for inclusion
in this review. Pain or pain relief may be measured by any type of
scale: numerical (including percentage), verbal, pictorial. The
desired outcome is 30% pain relief or pain < 5/10 or equivalent
on a numerical scale, or ’none’ or ’mild’ on a verbal scale.
• Adverse effects, including dropout or attrition.
Secondary outcomes
• Use of analgesics, as rescue analgesia or ongoing analgesic
intake.
• Disability, overall function, interference of pain with
normal life, or quality of life.
• Emotional distress, including anxiety, depression, traumatic
stress symptoms, overall mood.
• Global improvement, satisfaction, as rated by participant.
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Search methods for identification of studies
Searches will be conducted on electronic databases and web sites
and by handsearching reviews and reference lists.
Electronic searches
We will use Medical subject headings (MeSH) or equivalent and
text word terms. There will be no language restrictions. Searches
will be tailored to individual databases. The search strategy for
MEDLINE is shown in Appendix 2.
We will search the following electronic databases:
• CENTRAL (The Cochrane Library);
• MEDLINE (Ovid);
• EMBASE (Ovi);
• Web of Science (ISI);
• CINAHL (Ebsco);
• LILACS (Bireme);
• PsycINFO (Ovid).
Searching other resources
• OpenGrey (online database of reports and other grey
literature produced in Europe);
• Trials registers for details of ongoing trials: (
www.clinicaltrials.gov); the metaRegister of controlled trials (
www.controlled-trials.com/mrct); the WHO: International
Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/
trialsearch/);
• Reference lists of reviews and retrieved full papers;
• Citation searches on key articles;
• Online Library of the Rehabilitation and Research Centre
for Torture Victims (RCT, now Dignity);
• Tables of Contents from the top 10 most frequently cited
sources emerging from the search (expected to be journal issues);
• We will contact authors where necessary for additional
information.
Data collection and analysis
Selection of studies
Two of the authors (AW, EB) will independently undertake an
initial screening of titles and abstracts using the inclusion criteria,
with the aim of identifying studies which may be eligible and for
which the full paper should be obtained. Where abstracts are not
available electronically, or leave uncertainty about the criteria, we
will seek the full paper.
The full papers will be read and selected against the inclusion cri-
teria by two of the authors (EB, LH) independently. The final
list will be achieved after comparison, and disagreements will be
resolved by discussion; where there continues to be doubt or dif-
ference, a third review author (KA) will be consulted to achieve
consensus.
We will include a Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) flow chart in the full review
which will show the status of identified studies (Moher 2009) as
recommended in Part 2, Section 11.2.1 of theCochrane Handbook
(Higgins 2011). We will include studies in the review irrespective
of whether measured outcome data are reported in a ’usable’ way.
Data extraction and management
The following data will be extracted by two authors (EB, LH)
independently, using a form developed in previous reviews, and
checked for agreement before entry into RevMan. Where there is
disagreement, a third author (AW or KA, depending on the topic)
will be consulted to resolve the difference.
• Methods: study design.
• Methods - sources of bias: sequence generation, allocation
sequence concealment, blinding, incomplete outcome data,
study size; other concerns about bias.
• Participants: sample size at baseline and all post-treatment
assessment points used for analysis; adherence to or participation
in treatment; setting of intervention; baseline characteristics of
the sample (age, gender, nationality, ethnicity, type of torture
experienced, legal status if refugees or asylum seekers, living
situation, separation from close family members).
• Interventions: number of arms; types of interventions
(drugs, doses, intervention technique or school of therapy); types
of placebo/control condition; protocol for intervention; training
of practitioner/therapists.
• Outcomes: assessment points (collected; reported); self-
report versus other-report versus objective; psychometric
properties of assessment instruments; language(s) of assessment
and translation or interpretation.
• N of participants in each intervention group; sample size;
missing participants; completion rates.
• Funding source; key conclusions of study authors;
allegiance of the trial authors.
Assessment of risk of bias in included studies
Two authors (EB, LH) will independently assess risk of bias for
each study, using the criteria outlined in the Cochrane Handbook
(Higgins 2011) and adapted from those used by the Cochrane
Pregnancy andChildbirthGroup,with any disagreements resolved
by discussion. We will complete a ’Risk of bias’ table for each
included study using the ’Risk of bias’ tool in RevMan (RevMan
2014).
We will assess the following for each study.
Random sequence generation (checking for possible selection
bias). We will assess the method used to generate the allocation se-
quence as: low risk of bias (any truly random process, e.g. random
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number table; computer random number generator); unclear risk
of bias (method used to generate sequence not clearly stated).
Allocation concealment (checking for possible selection bias). The
method used to conceal allocation to interventions prior to as-
signment determines whether intervention allocation could have
been foreseen in advance of, or during recruitment, or changed
after assignment. We will assess the methods as: low risk of bias
(e.g. telephone or central randomisation; consecutively numbered
sealed opaque envelopes); unclear risk of bias (method not clearly
stated). Studies that do not conceal allocation (e.g. open list) will
be excluded.
Blinding of outcome assessment (checking for possible detection
bias). We will assess the methods used to blind study participants
and outcome assessors from knowledge of which intervention a
participant received.We will assess themethods as: low risk of bias
(study states that it was blinded and describes the method used
to achieve blinding, e.g. identical tablets; matched in appearance
and smell); unclear risk of bias (study states that it was blinded but
does not provide an adequate description of how it was achieved).
Incomplete outcome data (checking for possible attrition bias due
to the amount, nature and handling of incomplete outcome data).
We will assess the methods used to deal with incomplete data as:
low risk (< 10% of participants did not complete the study and/or
used ‘baseline observation carried forward’ analysis); unclear risk
of bias (used ’last observation carried forward’ analysis); high risk
of bias (used ’completer’ analysis).
Size of study (checking for possible biases confounded by small
size). We will assess studies as being at low risk of bias (≥ 200
participants per treatment arm); unclear risk of bias (50 to 199
participants per treatment arm); high risk of bias (< 50 participants
per treatment arm).
Measures of treatment effect
Dichotomous outcomes (e.g. improved/not improved) will be
analysed using odds ratios with 95% confidence intervals (CIs),
using random effects. Categorical outcomes with more than two
categories (such as improved, same, worse) will be re-categorised
into two groups. We will not calculate numbers needed to treat
for an additional beneficial/harmful outcome.
Continuous data will be analysed using standardised mean dif-
ferences (SMDs) or effect sizes, using pooled standard deviations
and weighting for sample size, and calculating the 95% CI, us-
ing random effects. SMDs will then be interpreted individually
with reference to the quality and reliability of the measure where
available. Where data are severely skewed, they will be normalised
where possible by transformation or, if this does not produce a
satisfactory distribution, will be dichotomised.
Unit of analysis issues
If there are two or more treatment or comparison groups, we will
combine the two into a single treatment or comparison group for
analysis.
In the case of cluster randomisation, we will adjust for the effects
of clustering using an intraclass correlation coefficient (ICC).
Dealing with missing data
We will contact study authors to request missing data required for
meta-analysis. Where standard deviations are missing and unob-
tainable from authors, we will calculate these where possible from
F, t, or P values, or from standard errors. If this is not possible,
we will treat the trial as having no useable data. We will identify
intention-to-treat (ITT) analysis as an important marker of effort
to reduce bias (see Assessment of risk of bias in included studies).
Assessment of heterogeneity
Heterogeneity, as indicated by the I² statistic, will be interpreted
using the Cochrane Handbook (Higgins 2011), with reference to
variation between studies.
Assessment of reporting biases
The search strategy is broad, particularly in the grey literature, in an
attempt to address publication bias. If there are sufficient numbers
of trials, we will use funnel plots to examine for publication bias.
Data synthesis
We will use RevMan 5.3 (RevMan 2014) software to conduct
meta-analysis wherever feasible. A random-effects model will be
used, given the various sources of diversity described above.Where
meta-analysis is not possible, we will provide a narrative summary
of evidence relating to the primary and secondary outcomes.
Subgroup analysis and investigation of heterogeneity
1. Child and adult studies will be analysed separately, since
methods and outcomes usually differ, as does the type of torture
experienced.
2. If there are sufficient trials, we will analyse separately by
type of pain and/or by treatment modality or specific treatment.
Sensitivity analysis
Where possible, we will use sensitivity analyses to assess the effect
of the different methodological decisions made throughout the
review process. We will test these decisions by successively remov-
ing:
1. quasi-RCTs to leave only RCTs;
2. cluster-randomised trials to leave individually-randomised
trials;
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3. trials using non-ITT methods to leave only those analysed
using ITT (to be considered ITT analysis, the analysis must
include all participants who entered treatment, whether or not
they provided data at the end of treatment: Nuesch 2009 has
found that trials with ITT analyses produce smaller treatment
effects in meta-analyses, and this difference is greater in meta-
analyses in the presence of heterogeneity); and
4. unpublished trials. Some treatment studies in this literature
are published in non-peer-reviewed sources, such as chapters and
internal reports of non-government organisations. To address
concerns about differences in quality between the two types of
source, sensitivity analyses will be undertaken, restricted to those
studies in peer-reviewed journals.
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A P P E N D I C E S
Appendix 1. GRADE assessment
The GRADE system uses the following criteria for assigning grades of evidence:
High = further research is very unlikely to change confidence in the estimate of effect
Moderate = further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate
Low = further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the
estimate
Very low = any estimate of effect is very uncertain
Grade of evidence if decreased further if the following are present:
• Serious (-1) or very serious (-2) limitation to study quality;
• Important inconsistency (-1);
• Some (-1) or major (-2) uncertainty about directness;
• Imprecise or sparse data (-1);
• High probability of reporting bias (-1).
Grade of evidence may be increased if:
• Strong evidence of association - significant relative risk of > 2 (< 0.5) based on consistent evidence from two or more
observational studies, with no plausible confounders (+1);
• Very strong evidence of association - significant relative risk of > 5 (< 0.2) based on direct evidence with no major threats to
validity (+2);
• Evidence of a dose response gradient (+1);
• All plausible confounders would have reduced the effect (+1).
Appendix 2. MEDLINE search strategy
MEDLINE (OVID) strategy
1. Torture/
2. torture*.tw.
3. 1 or 2
4. victim*.tw.
5. Survivors/
6. survivor*.tw.
7. survive*.tw.
8. or/4-7
9. exp Pain/ or Stress Disorders, Post-Traumatic/
10. pain*.tw.
11. exp chronic pain/ or exp intractable pain/
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12. ((chronic or persist*) adj2 pain).tw.
13. or/9-12
14. 3 and (8 or 13)
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